Mediastinal lymph node size in lung cancer

Using a size criterion of 1 cm or greater as evidence for abnormality, the size of mediastinal lymph nodes identified by computed tomography (CT) was a poor predictor of mediastinal lymph node metastases in a series of 86 patients who had surgery for bronchogenic carcinoma. The surgery included full nodal sampling in all patients. Of the 86 patients, 36 had nodes greater than or equal to 1 cm identified by CT. Of the 21 patients with mediastinal metastases proven at surgery, 14 had nodes greater than or equal to 1 cm (sensitivity = 67%). Of the 65 patients without mediastinal metastases, 22 had nodes greater than or equal to 1 cm. Specificity was 66% (43/65). Obstructive pneumonia and/or pulmonary collapse distal to the cancer was present in 39 patients (45%). Of these, 21 had mediastinal nodes greater than or equal to 1 cm; 10 harbored metastases and 11 did not. Obstructive pneumonia and/or pulmonary collapse is a common occurrence in bronchogenic carcinoma, but mediastinal nodes greater than or equal to 1 cm in this circumstance cannot be presumed to represent metastatic disease. Metastatic mediastinal lymph node involvement was related to nodal size also in patients with evidence of prior granulomatous disease and in patients with no putative benign cause for nodes greater than or equal to 1 cm. In both of these groups, metastatic nodal disease was found in only 25% of nodes greater than or equal to 1 cm.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. Bunyaviroch and R. E. Coleman PET Evaluation of Lung Cancer J. Nucl. Med., March 1, 2006; 47(3): 451 - 469. [Full Text] [PDF]

				M. G. Harisinghani, W. T. Dixon, M. A. Saksena, E. Brachtel, D. J. Blezek, P. J. Dhawale, M. Torabi, and P. F. Hahn MR Lymphangiography: Imaging Strategies to Optimize the Imaging of Lymph Nodes with Ferumoxtran-10 RadioGraphics, May 1, 2004; 24(3): 867 - 878. [Abstract] [Full Text] [PDF]

				J B Bingham Where can FDG-PET contribute most to anatomical imaging problems? Br. J. Radiol., November 1, 2002; 75(90009): S39 - 52. [Full Text] [PDF]

				N. Hollings and P. Shaw Diagnostic imaging of lung cancer Eur. Respir. J., April 1, 2002; 19(4): 722 - 742. [Abstract] [Full Text] [PDF]

				K. Takamochi, K. Nagai, J. Yoshida, K. Suzuki, Y. Ohde, M. Nishimura, K. Takahashi, and Y. Nishiwaki THE ROLE OF COMPUTED TOMOGRAPHIC SCANNING IN DIAGNOSING MEDIASTINAL NODE INVOLVEMENT IN NON-SMALL CELL LUNG CANCER J. Thorac. Cardiovasc. Surg., June 1, 2000; 119(6): 1135 - 1140. [Abstract] [Full Text] [PDF]

				K. Takamochi, K. Nagai, K. Suzuki, J. Yoshida, Y. Ohde, and Y. Nishiwaki Clinical Predictors of N2 Disease in Non-small Cell Lung Cancer Chest, June 1, 2000; 117(6): 1577 - 1582. [Abstract] [Full Text] [PDF]

				C. A.B. Saunders, J. E. Dussek, M. J. O'Doherty, and M. N. Maisey Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer Ann. Thorac. Surg., March 1, 1999; 67(3): 790 - 797. [Abstract] [Full Text] [PDF]